Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Movement disorders 2006-01, Vol.21 (1), p.115-116
Hauptverfasser:	Sullivan, Kelly L., Staffetti, Joseph F., Hauser, Robert A., Dunne, Peter B., Zesiewicz, Theresa A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences constipation Constipation - drug therapy Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Double-Blind Method Female Gastrointestinal Agents - administration & dosage Gastrointestinal Motility - drug effects Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Indoles - administration & dosage Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Parkinson Disease - drug therapy Parkinson's disease Patient Satisfaction Serotonin 5-HT4 Receptor Agonists Serotonin Receptor Agonists - administration & dosage tegaserod Zelnorm
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society
ISSN:	0885-3185 1531-8257
DOI:	10.1002/mds.20666